# US 2025/0152633 A1 · Cells having improved proliferative capacity and reduced cellular senescence

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152633 A1
- Document ID: US20250152633A1
- Status: Published application
- Kind: A1
- Application number: 18/884,506
- Filed: 2024-09-13
- Published: 2025-05-15
- Earliest claimed: 2023-09-13
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, the University of Texas System
- Inventors: Aaron BAKER; Miles MASSIDDA
- Web page: https://patentgrep.com/patent/US20250152633A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- C12N 13/00: Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
- C12N 2500/32: Amino acids
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/999: Small molecules not provided for elsewhere
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are methods for mechanically conditioning cells to improve their proliferative function and multipotency, as well as protect them from advancing senescence. In the methods, brachial loading alone is first used to improve the efficiency of culture expansion. Once a sufficient population of healthy cells are generated, pharmacological agents are added as a cotreatment to drive differentiation into a desired phenotype. The conditioned cells may then be used to prepare compositions for administration to a patient to treat a disease.

## Claims

### Claim 1

A method of preparing a therapeutic cell population, the method comprising:
(a) adhering a starting population of cells on a flexible or expandable surface;
(b) applying a brachial waveform of mechanical stretch to the starting population of cells, thereby generating a second population of cells;
(c) expanding the second population of cells under static conditions; and
(d) applying a brachial waveform of mechanical stretch to the expanded second population of cells in the presence of at least one pharmacological agent that induces differentiation of the cells, thereby generating the therapeutic population of cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the brachial waveform mechanical stretch in step (b) and/or step (d) is applied to the cells for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, or 10 days.

### Claim 3 (depends on 1)

The method of claim 1, wherein the brachial waveform mechanical stretch in step (b) and/or step (d) is applied to the cells for about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, or about 8 hours per day.

### Claim 4 (depends on 1)

The method of claim 1, wherein the brachial waveform mechanical stretch in step (b) and/or step (d) is applied to the cells for about 4 hours per day for 7 days.

### Claim 5 (depends on 1)

The method of claim 1, wherein the brachial waveform in step (b) and/or step (d) has a frequency of 0.01 Hz-1.00 Hz.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the brachial waveform in step (b) and/or step (d) has a magnitude of strain of 0.1% to 17.5%.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the brachial waveform in step (b) and/or step (d) has a magnitude of 7.5% strain and a frequency of 0.1 Hz.

### Claim 10 (depends on 1)

The method of claim 1, wherein step (b) comprises applying a brachial waveform of mechanical stretch to the starting population of cells for about 4 hours per day for about 7 days; step (c) comprises expanding the second population of cells under static conditions for at least about 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, or 8 weeks; and step (d) comprises applying a brachial waveform of mechanical stretch to the expanded second population of cells in the presence of at least one pharmacological agent that induces differentiation of the cells for about 4 hours per day for about 7 days.

### Claim 11 (depends on 1)

The method of claim 1, wherein the at least one pharmacological agent that induces differentiation of the cells is an agent that inhibits signaling of at least one ErbB family protein.

### Claim 12 (depends on 1)

The method of claim 1, wherein step (b) comprises applying a brachial waveform of mechanical stretch to the starting population of cells for about 4 hours per day for about 7 days; step (c) comprises expanding the second population of cells under static conditions for at least about 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, or 8 weeks; and step (d) comprises applying a brachial waveform of mechanical stretch to the expanded second population of cells in the presence of at least one pharmacological agent that inhibits signaling of at least one ErbB family protein for about 4 hours per day for about 7 days.

### Claim 13 (depends on 11)

The method of claim 11, wherein the agent that inhibits signaling of at least one ErbB family protein inhibits EGFR/ErbB1 signaling, HER2/ErbB2 signaling, HER4/ErbB4 signaling, or EGFR/PKC signaling.

### Claim 14

(canceled)

### Claim 15 (depends on 11)

The method of claim 11, wherein the agent that inhibits signaling of at least one ErbB family protein is a kinase inhibitor.

### Claim 16 (depends on 15)

The method of claim 15, wherein the kinase inhibitor is an EGFR/Erb-2/4 inhibitor or a PKCβII/EGFR inhibitor.

### Claim at position 17

17-25. (canceled)

### Claim 26 (depends on 1)

The method of claim 1, wherein the starting population of cells is senescent.

### Claim at position 19

27-43. (canceled)

### Claim 44 (depends on 1)

The method of claim 1, further comprising
(e) encapsulating the population of therapeutic cells in a gel delivery vehicle.

### Claim 45 (depends on 44)

The method of claim 44, wherein the gel delivery vehicle is an alginate-RGD-collagen gel delivery vehicle.

### Claim 46 (depends on 1)

The method of claim 1, further comprising
(e) culturing the population of therapeutic cells on a tissue engineering scaffold to generate a tissue-engineered construct.

### Claim 47 (depends on 1)

A population of therapeutic cells produced by the method of claim 1.

### Claim 48 (depends on 47)

A composition comprising the population of therapeutic cells of claim 47.

### Claim at position 25

49-52. (canceled)

### Claim 53 (depends on 48)

A method of treating a patient in need thereof comprising administering a therapeutically effective amount of the composition of claim 48 to the patient.

### Claim at position 27

54-63. (canceled)
